Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Janet S. Macpherson"'
Autor:
Janet S. Macpherson, Sylvie Guichard, Duncan I. Jodrell, Eilidh Reid, Iain Mayer, Susan Alexander, Michael Dodds, Morwenna Muir
Publikováno v:
European Journal of Cancer. 44:310-317
Capecitabine is converted into 5'-deoxy-5-fluorocytidine (5'DFCR), 5'-deoxy-5-fluorouridine (5'DFUR) and 5-fluorouracil (5-FU) by CES1 and 2, CDD, and TP, in both liver and tumour. 5-FU is catabolised by DPD. Gene expression analysis of these enzymes
Autor:
David E. Thurston, Janet S. Macpherson, Marian Thomson, Rhona Aird, Duncan I. Jodrell, Sylvie Guichard
Publikováno v:
The Pharmacogenomics Journal. 8:289-296
ATP-binding cassette transporter P-glycoprotein (ABCB1) is responsible for the multidrug resistance (MDR1) phenotype observed in cancer cells. SJG-136, a new pyrrolobenzodiazepine dimer, is a sequence-dependent DNA crosslinking agent and substrate of
Autor:
John F. Smyth, Duncan I. Jodrell, Gillian Smith, Janet S. Macpherson, Helga Wolf, Jeffrey Cummings, Gary Boyd
Publikováno v:
Cancer Chemotherapy and Pharmacology. 49:194-200
Purpose: The influence of biophysical factors (drug metabolism, transport proteins, and chemical stability) on the cellular accumulation of camptothecin (CPT) and SN-38 was examined. Methods: Drug transporter RNA transcript levels were measured by re
Autor:
Janet S. Macpherson, John F. Smyth, Brian Burchell, Jeffrey Cummings, Duncan I. Jodrell, Brian T. Ethell, Gary Boyd
Publikováno v:
Biochemical Pharmacology. 63:607-613
As part of a program to identify novel mechanisms of resistance to topoisomerase I (topo I) inhibitors, the cellular pharmacology of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of clinically used irinotecan (CPT-11) and NU/ICRF 505,
Publikováno v:
Journal of Chromatography B: Biomedical Sciences and Applications. 685:159-164
A high-performance liquid chromatographic technique is presented for the determination of the novel topoisomerase I inhibitor NU/ICRF 505 (a tyrosine conjugate of anthraquinone), its major metabolite (NU/ICRF 505/M) and an internal standard (NU/ICRF
Publikováno v:
British Journal of Cancer
Anthracenyl-amino acid conjugates represent a novel chemical class of topoisomerase (topo) inhibitor. NU/ICRF 505 is a lead compound that stabilises topo I cleavable complexes and is actively cytotoxic at low microM concentrations. In this study, end
Publikováno v:
Biochemical Pharmacology. 49:1747-1757
Mono-conjugation of an anthraquinone nucleus with a range of naturally occurring amino acids chemically modified at their C-terminus has been adopted as a synthetic approach in the rational design of novel topoisomerase (topo) inhibitors. The biochem
Autor:
David E. Thurston, Janet S. Macpherson, John A. Hartley, Victoria J. Spanswick, Duncan I. Jodrell, Sylvie Guichard, Stéphanie Arnould
Publikováno v:
Molecular cancer therapeutics. 5(6)
SJG-136 is a new pyrrolobenzodiazepine dimer inducing time-dependent cytotoxicity. HCT 116 cells were exposed to 50 nmol/L of SJG-136 for 1 hour or 1 nmol/L of SJG-136 for 24 hours to achieve similar levels of interstrand cross-links (ICL). The short
Publikováno v:
Analytical biochemistry. 350(1)
Capecitabine is an oral fluoropyrimidine carbamate activated sequentially in both liver and tumor tissues by carboxylesterases, cytidine deaminase, and thymidine phosphorylase. 5-Fluorouracil is inactivated by dihydropyrimidine dehydrogenase and targ
Publikováno v:
European journal of cancer (Oxford, England : 1990). 41(12)
SJG-136 is a novel pyrrolobenzodiazepine dimer analogue that acts as a minor-groove interstrand DNA cross-linking agent. The present study investigated the impact of ABCB1 (mdr-1) expression on the activity of SJG-136 using both in vitro and in vivo